InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

- Current share price for ATX : $0.150

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$77 Summary Results - Successful Phase 1 Clinical Trial AMP945 18 Nov 2021 8:54AM $0.190 $0.150 fallen by 21.05%
$77 Inhibition of FAK by AMP945 in Phase 1 Clinical Trial 17 Nov 2021 8:25AM $0.185 $0.150 fallen by 18.92%
$77 Becoming a substantial holder 16 Nov 2021 2:29PM $0.190 $0.150 fallen by 21.05%
$77 Application for quotation of securities - ATX 15 Nov 2021 5:19PM $0.185 $0.150 fallen by 18.92%
$77 Change in substantial holding 15 Nov 2021 4:21PM $0.185 $0.150 fallen by 18.92%
$77 Application for quotation of securities - ATX 15 Nov 2021 9:39AM $0.190 $0.150 fallen by 21.05%
$77 Section 708A Cleansing Notice - Share Placement 12 Nov 2021 4:51PM $0.190 $0.150 fallen by 21.05%
$77 Blueflag Holding - Change of Interest of Substantial Holder 12 Nov 2021 4:16PM $0.190 $0.150 fallen by 21.05%
$77 Application for quotation of securities - ATX 12 Nov 2021 9:47AM $0.190 $0.150 fallen by 21.05%
$77 Proposed issue of securities - ATX 8 Nov 2021 9:54AM $0.195 $0.150 fallen by 23.08%
$77 Proposed issue of securities - ATX 8 Nov 2021 9:54AM $0.195 $0.150 fallen by 23.08%
$77 Capital Raising Investor Presentation 8 Nov 2021 9:51AM $0.195 $0.150 fallen by 23.08%
$77 Entitlement Offer Prospectus 8 Nov 2021 9:49AM $0.195 $0.150 fallen by 23.08%
$77 Placement and Underwritten Entitlement Offer to Raise $12.4m 8 Nov 2021 9:48AM $0.195 $0.150 fallen by 23.08%
$77 Amplia and CRUK agree to Amend Licence Terms - AMP886 4 Nov 2021 9:42AM $0.195 $0.150 fallen by 23.08%
$77 Trading Halt 4 Nov 2021 9:23AM $0.195 $0.150 fallen by 23.08%
$77 Quarterly Activities and Cashflow Reports - Sep 2021 Qtr 27 Oct 2021 12:53PM $0.200 $0.150 fallen by 25%
$77 Amplia Appoints New Oncology Clinical Advisor 26 Oct 2021 9:05AM $0.195 $0.150 fallen by 23.08%
$77 Amplia Provides Updated Investor Presentation 19 Oct 2021 10:33AM $0.195 $0.150 fallen by 23.08%
$77 Amplia Receives $1.1m R&D Tax Incentive 14 Oct 2021 10:31AM $0.195 $0.150 fallen by 23.08%
$77 Amplia Appoints New Chief Financial Officer 1 Oct 2021 11:53AM $0.220 $0.150 fallen by 31.82%
$77 New Garvan Publication Supports Amplia Phase 2 Design 30 Sep 2021 9:07AM $0.200 $0.150 fallen by 25%
$77 Proactive Investors Lifesciences Webinar Presentation 28 Sep 2021 8:25AM $0.200 $0.150 fallen by 25%
$77 Amplia to Present at Proactive Investor Lifesciences Webinar 27 Sep 2021 8:40AM $0.210 $0.150 fallen by 28.57%
$77 Phase 2 Trial in First-Line Pancreatic Cancer Patients 15 Sep 2021 9:10AM $0.200 $0.150 fallen by 25%

326 - 350 of 538 results

Page 14 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.